A Phase 1 Study of RO7623066 Alone and in Combination in Patients With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT05240898. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 1 study to assess the safety and clinical activity of RO7623066 alone and in combination in patients with advanced solid tumors.
Study identification
- NCT ID
- NCT05240898
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 116 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 25, 2021
- Primary completion
- Nov 25, 2025
- Completion
- Nov 25, 2025
- Last update posted
- Dec 17, 2025
2021 – 2025
United States locations
- U.S. sites
- 15
- U.S. states
- 12
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Irvine Medical Center | Orange | California | 92868 | — |
| Yale School of Medicine | New Haven | Connecticut | 06510-3206 | — |
| Barbara Ann Karmanos Cancer Institute | Detroit | Maine | 48201-2013 | — |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| South Texas Accelerated Research Therapeutics (START) - Midwest Location | Grand Rapids | Michigan | 49546 | — |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | — |
| Cleveland Clinic, | Cleveland | Ohio | 44195 | — |
| The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Oregon Health & Science University | Portland | Oregon | 97239 | — |
| Rhode Island Hospital | Providence | Rhode Island | 02906 | — |
| Mary Crowley Medical Research Center | Dallas | Texas | 75230 | — |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77030-4009 | — |
| South Texas Accelerated Research Therapeutics (START) | San Antonio | Texas | 98229 | — |
| University of Virginia Health System | Charlottesville | Virginia | 22908 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05240898, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 17, 2025 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05240898 live on ClinicalTrials.gov.